G

    Globus Medical (GMED)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $81.38
    -1.59 (-1.92%)

    Market Cap: $11.14B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +13.63%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$1.19
    Range$1.13 - $1.22
    14 analysts
    EPS Revisions
    7
    0
    7d
    6
    0
    30d
    EPS Estimate Drift
    90d ago$1.16-2.1%
    60d ago$1.17-1.6%
    30d ago$1.17-1.6%
    7d ago$1.19+0.0%
    Current$1.19
    Revenue Consensus
    $792M
    Range$776M - $802M
    15 analysts
    Dec 31, 2026
    EPS Consensus$1.77
    Range$1.55 - $1.82
    15 analysts
    Revenue Consensus
    $884M
    Range$865M - $901M
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.77---
    Sep 26EST
    		-$1.19---
    Jun 26
    		$1.34$1.12+19.64%Beat+55.8%
    Mar 26
    		$1.12$0.92+21.74%Beat+64.7%
    Dec 25
    		$1.28$1.15+10.96%Beat+52.4%
    Sep 25
    		$1.18$0.78+51.28%Beat+42.2%
    Jun 25
    		$0.86$0.76+13.16%Beat+14.7%
    Mar 25
    		$0.68$0.75-9.33%Miss-5.6%
    Dec 24
    		$0.84$0.75+12.21%Beat+40.0%
    Sep 24
    		$0.83$0.65+27.69%Beat+45.6%
    Jun 24
    		$0.75$0.68+10.29%Beat+19.0%
    Mar 24
    		$0.72$0.57+26.32%Beat+35.8%
    Dec 23
    		$0.60$0.61-1.64%Miss+1.7%
    Sep 23
    		$0.57$0.57+0.00%Beat+14.0%
    Jun 23
    		$0.63$0.59+6.78%Beat+12.5%
    Mar 23
    		$0.53$0.51+3.92%Beat+26.2%
    Dec 22
    		$0.59$0.56+5.36%Beat+20.4%
    Sep 22
    		$0.50$0.52-3.85%Miss+0.0%
    Jun 22
    		$0.56$0.53+5.66%Beat+0.0%
    Mar 22
    		$0.42$0.47-10.64%Miss-14.3%
    Dec 21
    		$0.49$0.47+4.26%Beat-15.5%
    Sep 21
    		$0.50$0.45+11.11%Beat+2.0%
    Jun 21
    		$0.56$0.44+27.27%Beat+700.0%
    Mar 21
    		$0.49$0.37+32.43%Beat+69.0%
    Dec 20
    		$0.58$0.51+13.73%Beat+18.4%
    Sep 20
    		$0.49$0.31+58.06%Beat+14.0%
    Jun 20
    		$0.07$-0.11+163.64%Beat-82.9%
    Mar 20
    		$0.29$0.38-23.68%Miss-19.4%
    Dec 19
    		$0.49$0.52-5.77%Miss+14.0%
    Sep 19
    		$0.43$0.42+2.38%Beat+10.3%
    Jun 19
    		$0.41$0.41+0.00%Beat-6.8%
    Mar 19
    		$0.36$0.41-12.20%Miss-12.2%
    Dec 18
    		$0.43$0.39+10.26%Beat+13.2%
    Sep 18
    		$0.39$0.32+21.88%Beat+30.0%
    Jun 18
    		$0.44$0.35+25.71%Beat+37.5%
    Mar 18
    		$0.41$0.36+13.89%Beat+36.7%
    Dec 17
    		$0.38$0.35+8.57%Beat+22.6%
    Sep 17
    		$0.30$0.30+0.00%Beat+3.4%
    Jun 17
    		$0.32$0.30+6.67%Beat-
    Mar 17
    		$0.30$0.30+0.00%Beat-
    Dec 16
    		$0.31$0.33-6.06%Miss-
    Sep 16
    		$0.29$0.28+3.57%Beat-

    Key Metrics

    Valuation
    P/E Ratio16.54EV/EBITDA11.11x
    Price/FCF14.55xFCF Yield6.87%
    Profitability
    Profit Margin17.00%Operating Margin24.80%
    ROE11.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage2.76x
    Current Ratio4.62xQuick Ratio2.93x
    Trading Statistics
    Beta0.95Avg Volume1.35M
    52-Week High$101.4052-Week Low$54.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$84.44
    SMA 20$84.19
    SMA 50$81.15
    SMA 200$85.99
    EMA 10$83.50
    EMA 20$83.34
    EMA 50$82.36
    EMA 200$81.54

    MACD

    Line: 0.56Signal: 1.17Hist: -0.61

    ADX

    ADX: 15.5+DI: 19.8-DI: 21.4

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$87.15

    Bollinger Bands

    Upper Band$88.64
    Lower Band$79.74
    %B Position1057%(Upper)
    Band Width0.18

    RSI (14-Day)

    Neutral
    45.3

    Momentum Oscillators

    Stoch %K12.7
    Stoch %D20.7
    Williams %R-95.2
    ROC (10d)-4.4%
    Momentum-3.74
    CCI (20d)-96.7
    MFI (14d)38.6

    Volatility Measures

    ATR (14d)$2.49(3.1%)
    StdDev (20d)2.23
    Hist Vol29.0%(Moderate)

    Volume Flow

    VWAP$81.51
    OBV-14.6M
    AD Line9.4M
    CMF (20d)0.134

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.7x
    VWMA (20d)$84.04

    Pivot Points

    R3$85.46
    R2$84.50
    R1$83.73
    Pivot Point$82.77
    S1$82.00
    S2$81.04
    S3$80.27

    Advanced Oscillators

    TSI6.21
    Ultimate Osc44.0
    KST64.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$789.61M$759.85M$826.42M$769.05M$745.34M$598.12M$657.29M$625.71M$629.69M$606.67M$616.53M$383.64M
    Cost of Revenue$241.44M$234.07M$261.11M$252.53M$248.76M$195.40M$263.44M$270.51M$260.04M$241.49M$265.49M$135.39M
    Gross Profit$548.17M$525.79M$565.31M$516.51M$496.58M$402.72M$393.86M$355.19M$369.65M$365.18M$351.05M$248.25M
    Operating Expenses$365.74M$375.40M$395.97M$379.15M$420.47M$305.72M$333.58M$307.09M$320.03M$357.18M$340.93M$247.84M
    R&D$36.32M$36.51M$36.16M$38.07M$39.95M$33.06M$33.41M$35.38M$37.70M$57.27M$52.25M$29.33M
    SG&A$286.82M$297.77M$318.48M$313.60M$303.62M$242.80M$253.17M$240.06M$239.45M$248.68M$245.15M$156.21M
    Operating Income$182.43M$150.39M$169.34M$137.36M$76.11M$97.00M$60.27M$48.10M$49.62M$8.00M$10.12M$404,000
    Interest Income$7.07M$5.43M$0$0$693,000$1.68M$0$0$0$0$0$0
    Interest Expense$0$0$107,000$-1,455,000$0$0$35.61M$775,000$2.33M$1.89M$0$-7,920,000
    Income Before Tax$189.82M$157.07M$169.23M$143.99M$188.17M$103.67M$24.67M$57.03M$47.58M$-8,558,000$25.00M$2.54M
    Income Tax Expense$38.25M$32.77M$28.64M$25.03M$-14,673,000$28.21M$-1,838,000$5.20M$15.82M$-1,441,000$9.96M$1.54M
    Net Income$151.57M$124.30M$140.59M$118.97M$202.85M$75.46M$26.50M$51.84M$31.76M$-7,117,000$15.03M$998,000
    EBITDA$252.24M$221.50M$241.89M$220.57M$264.08M$174.35M$145.54M$192.06M$173.79M$108.95M$159.57M$51.01M
    EBIT$182.74M$151.64M$165.92M$142.54M$187.48M$101.99M$23.85M$57.81M$49.92M$-6,664,000$27.58M$-5,385,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Globus Medical Grew Earnings 56% On 6% Revenue. The Robotics Line Went Backwards.

    Q2 non-GAAP EPS $1.34, up 55.8% y/y; revenue $789.6M, +5.9%; company kept revenue guide $3.18-3.22B and raised adjusted EPS to $4.95-5.05 from $4.70-4.80 Enabling Technologies revenue fell 25.8% to $26.1M, now 3.3% of sales - robotics is a marginal, shrinking contributor, so treat any robotics pull-through thesis as unproven Adjusted gross margin expanded 200bps to 69.4%; SG&A down $16.8M to $286.8M, SG&A margin improved 440bps to 36.3%; R&D fell to 4.6% of sales - 40-140bps of margin tailwind likely temporary 1H operating cash flow $412.1M vs $255.2M y/y; 1H free cash flow $339.3M vs $172.5M; cash and marketable securities $840.5M, net cash ~$6.26/sh, trading near 15x 2024E EPS or 13.3x trailing FCF Neuromodulation down 14.3% and not expected to recover until late Q4; U.S. sales +3% with spine +7% while international +18% - prefer mid-$70s entry given cost-driven EPS gains and revenue risks

    Unknown Author
    •
    8/11/26
    •
    179
    Medical Devices
    value investing
    Also mentions:
    MDT
    ISRG

    Government Contracts

    Gov Obligations (TTM)
    $9453
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    145
    New Awards (TTM)
    136
    Avg Remaining Term
    6.0 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25725C0056Department of Veterans AffairsDepartment of Veterans Affairs$231000Sep 19, 2025
    HT941026PE042Department of DefenseDefense Health Agency$64186Feb 20, 2026
    HT941026PE024Department of DefenseDefense Health Agency$61379Jan 15, 2026
    SPE2D625F0ZEXDepartment of DefenseDefense Logistics Agency$44763Aug 14, 2025
    SPE2D626F05TKDepartment of DefenseDefense Logistics Agency$42475Jan 13, 2026
    SPE2D625F1WRZDepartment of DefenseDefense Logistics Agency$34092Aug 5, 2025
    HT940625PE017Department of DefenseDefense Health Agency$32065Sep 22, 2025
    SPE2D626F30QEDepartment of DefenseDefense Logistics Agency$31415Jan 28, 2026
    HT001425PE042Department of DefenseDefense Health Agency$29522Sep 15, 2025
    SPE2D626F26JHDepartment of DefenseDefense Logistics Agency$27380Jan 22, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Globus Medical (GMED) Could Be 17% Undervalued On Its Robotics Growth Narrative

    Globus Medical (GMED) is considered potentially undervalued despite strong historical returns and a P/E ratio below industry averages, driven by improved adjusted EBITDA margins. The company's fair value is estimated at $103.23 against a last close of $85.67, with growth expected from its robotics, navigation, and minimally invasive procedures, including the ExcelsiusGPS ecosystem and Excelsius XR headset. However, potential challenges include hospital capital spending and successful integration with NuVasive and Nevro.

    Sahm•8/22/26•
    Somewhat-Bullish

    Globus Medical Director Sold Shares Worth Over $2.1M

    Stephen T. Zarrilli, a Director at Globus Medical (GMED), sold Class A Common Stock on August 18, 2026, totaling $2,175,965. The shares were sold at a weighted average price of $87.0386, ranging from $86.92 to $87.16. Following this transaction, Zarrilli no longer directly owns Class A Common Stock.

    TradingView•8/20/26•
    Somewhat-Bearish

    Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026

    Globus Medical Director Stephen T. Zarrilli exercised stock options for 25,000 shares of Class A Common Stock on August 18, 2026, at $53.27 per share. On the same day, he sold all 25,000 shares at a weighted average price of $87.0386 per share, resulting in zero direct beneficial ownership of Globus Medical stock after the transactions. The options were granted in January 2020 and were fully vested.

    Kalkine Media•8/20/26•
    Neutral

    Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares

    Globus Medical (NYSE: GMED) director Stephen T. Zarrilli exercised 25,000 stock options at $53.27 per share and subsequently sold all 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share. This transaction resulted in approximately $844,000 pre-tax spread for the director. The options were fully vested and granted on January 22, 2020.

    Stock Titan•8/19/26•
    Neutral

    Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?

    Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While revenue guidance remains firm, investors are urged to consider margin pressure and acquisition risks that could affect future profitability.

    Sahm•8/17/26•
    Neutral

    Frequently Asked Questions About GMED

    Does GMED pay dividends?
    Globus Medical (GMED) does not currently pay a regular dividend.
    What is GMED's P/E ratio?
    Globus Medical has a price-to-earnings (P/E) ratio of 16.54.
    What is GMED's market cap?
    Globus Medical (GMED) has a market capitalization of $11.14B with a current stock price of $81.38.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In